PrECOG Cancer Research Group

PrECOG Cancer Research Group Innovative cancer research studies developed through industry partnerships and networks.

Supporting ECOG-ACRIN Cancer Research Group's efforts to advance cancer care

research study PrE1702, led by Dr. Suzanne Cole of UT Southwestern, aims to discover if osimertinib with or without ch...
03/17/2026

research study PrE1702, led by Dr. Suzanne Cole of UT Southwestern, aims to discover if osimertinib with or without chemotherapy has the same benefits for patients receiving treatment outside of a as for those in a trial. Learn more: https://bit.ly/pre1702-study

Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell...
03/13/2026

Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell lung cancer ( ) who have not yet had systemic therapy. Learn more: https://bit.ly/PrE0510

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive in patients not participating in ...
03/10/2026

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive in patients not participating in a clinical trial? The PrE1702 research study aims to find out. Learn more: https://bit.ly/pre1702-study

The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo...
03/06/2026

The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: https://bit.ly/PrE0510

The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-posit...
03/03/2026

The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study

The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo...
02/27/2026

The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: https://clinicaltrials.gov/study/NCT07057791

PrE0510 is a randomized phase 2 clinical trial exploring the optimal dose of ivonescimab with carboplatin and etoposide ...
02/20/2026

PrE0510 is a randomized phase 2 clinical trial exploring the optimal dose of ivonescimab with carboplatin and etoposide in extensive-stage small cell lung cancer ( ). For more information: https://clinicaltrials.gov/study/NCT07057791

Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell...
02/13/2026

Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell lung cancer ( ) who have not yet had systemic therapy. Learn more: https://clinicaltrials.gov/study/NCT07057791

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive Lung Cancer in patients not partici...
02/10/2026

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive Lung Cancer in patients not participating in a clinical trial? The PrE1702 research study aims to find out. More: https://bit.ly/pre1702-study

Address

1818 Market Street, Suite 3000
Philadelphia, PA
19118

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+12157897001

Website

Alerts

Be the first to know and let us send you an email when PrECOG Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

PrECOG, LLC develops and leads research that provides new hope for patients and their families. This is accomplished through innovation, working with oncology research leaders, partnerships with research groups, and collaborations with industry partners. Our goal is to design, implement, and publish results for clinical trials that support the ever-evolving needs of patients with cancer and our underlying knowledge of cancer diseases.